CAI
NASDAQ
US
Caris Life Sciences, Inc. - Common Stock
$19,29
▲ +$0,16
(+0,84%)
Vol. 1.5M
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$7.6B
Margine
-46,4%
D/E
78,70
Beta
0,30
52W
$23–$43
Consenso Wall Street
14 analisti · Apr 20266
Acquisto forte
6
Compra
2
Mantieni
0
Vendi
0
Vendita forte
85,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8,1
$6.1B
ERAS
Erasca Inc
$1.1B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10,6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70,7
$3.2B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
Utili
Tasso di battuta: 66,7%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $0,03 | $0,28 | +$0,25 |
| Set 2025 | $-0,21 | $0,08 | +$0,29 |
| Giu 2025 | $-0,20 | $-7,97 | $-7,77 |
Ricavi e utili trimestrali
| Trimestre | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|
| Ricavi | $120.9M | $181.4M | $216.8M | $292.9M |
| Utile netto | -$102.6M | -$71.8M | $24.3M | $82.0M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | — | — | — | — | — |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -39.6% | — | -63.9% | -63.9% | -46.4% | -46.4% |
| Gross Margin | 62.7% | — | 49.1% | 49.1% | 53.5% | 53.5% |
| D/E Ratio | 82.51 | — | 82.51 | 82.51 | 78.70 | 78.70 |
| Current Ratio | 9.24 | 1.05 | 9.24 | 9.24 | 9.93 | 9.93 |
Rapporti chiave
P/S (TTM)
8,17
EPS (TTM)
$-1,56
52W High
$42,50
52W Low
$22,86
$22,86
Intervallo 52 settimane
$42,50
Salute finanziaria
Flusso di cassa libero
$39.7M
Debito netto
-$368.6M
Liquidità
$796.3M
Debito totale
$427.7M
Aggiornato al Dic 31, 2025
Як CAI виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CAI vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
8,2
▼
36%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
—
▼
0%
sotto
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CAI vs аналоги Biotechnology
ROE
—
▼
0%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
-46,4%
▲
84%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
53,5%
▼
32%
sotto
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
—
▼
0%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя CAI vs аналоги Biotechnology
D/E ratio
78,7
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
9,9
▲
124%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,3
▼
69%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CAI
CAI
Mediana peer
Industria
CAI прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio